STAAR Surgical Company (STAA) Income Statement
STAA 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsSTAA revenue and net income
Where STAA's revenue goes
2025Each bar shows an amount and its share of revenue. STAA kept −33.6% of revenue as net income.
STAA profit margins
STAA growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −23.7% | −5.6% | +7.9% | +12.0% |
| Gross profit | −23.9% | −6.5% | +9.0% | +13.2% |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | −8,300.0% | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
STAA quarterly EPS vs estimates
STAAR Surgical beat the analyst EPS estimate in 5 of the last 8 quarters. Next report: November 4, 2026 (estimate $0.05).
STAA income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $239.4M | $313.9M | $322.4M | $284.4M | $230.5M | $163.5M | $150.2M | $124.0M | $90.6M | $82.4M |
| Cost of revenue | $57.0M | $74.3M | $69.8M | $61.0M | $51.8M | $45.1M | $38.2M | $32.4M | $26.3M | $24.1M |
| Gross profit | $182.4M | $239.6M | $252.7M | $223.4M | $178.6M | $118.4M | $112.0M | $91.5M | $64.3M | $58.4M |
| Research & development | $40.1M | $54.0M | $44.4M | $36.0M | $33.9M | $31.9M | $25.3M | $22.0M | $19.1M | $20.3M |
| Sales, general & admin | $188.3M | $198.2M | $180.2M | $143.6M | $111.4M | $79.7M | $74.8M | $62.9M | $48.8M | $50.7M |
| Total operating expenses | $228.4M | $252.2M | $224.6M | $179.6M | $145.3M | $111.6M | $100.1M | $84.9M | $67.9M | $71.0M |
| Operating income | −$45.9M | −$12.6M | $28.1M | $43.8M | $33.3M | $6.8M | $11.9M | $6.6M | −$3.6M | −$12.7M |
| Interest income | $4.6M | $5.9M | $7.0M | $2.4M | — | $238,000 | $988,000 | — | — | $3,000 |
| Interest expense | — | — | — | $2.4M | $38,000 | $2.4M | $657,000 | $165,000 | $112,000 | $115,000 |
| Income before taxes | −$82.3M | −$9.1M | $33.7M | $45.6M | $31.3M | $8.3M | $13.0M | $6.6M | −$2.3M | −$12.4M |
| Income taxes | −$1.8M | $11.2M | $12.3M | $5.9M | $3.8M | $2.4M | −$1.0M | $1.7M | −$157,000 | −$315,000 |
| Net income | −$80.4M | −$20.2M | $21.3M | $39.7M | $27.5M | $5.9M | $14.0M | $5.0M | −$2.1M | −$12.1M |
| EBITDA | −$73.9M | −$2.2M | $38.8M | $50.1M | $35.0M | $9.9M | $15.6M | $9.1M | −$277,000 | −$9.7M |
| EPS (diluted) | −$0.82 | $0.01 | $1.04 | $1.22 | $0.87 | $0.36 | $0.47 | $0.27 | $0.01 | −$0.03 |
| Gross margin | 76.2% | 76.3% | 78.4% | 78.5% | 77.5% | 72.4% | 74.5% | 73.8% | 70.9% | 70.8% |
| Operating margin | −19.2% | −4.0% | 8.7% | 15.4% | 14.5% | 4.1% | 7.9% | 5.3% | −4.0% | −15.4% |
| Net margin | −33.6% | −6.4% | 6.6% | 13.9% | 11.9% | 3.6% | 9.4% | 4.0% | −2.4% | −14.7% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $93.5M | $93.5M | $57.8M | $94.7M | $44.3M | $42.6M | $49.0M | $88.6M | $99.0M | $77.4M | $76.3M | $80.3M |
| Cost of revenue | $23.8M | $26.0M | $14.1M | $16.9M | $11.5M | $14.6M | $17.3M | $20.1M | $20.6M | $16.3M | $15.5M | $16.7M |
| Gross profit | $69.7M | $67.5M | $43.7M | $77.9M | $32.8M | $28.0M | $31.6M | $68.5M | $78.4M | $61.0M | $60.7M | $63.6M |
| Research & development | $9.9M | $9.7M | $9.2M | $9.2M | $10.3M | $13.7M | $12.0M | $14.5M | $11.9M | $13.4M | $10.9M | $11.5M |
| Sales, general & admin | $49.7M | $40.4M | $45.4M | $44.2M | $47.3M | $49.1M | $47.5M | $48.3M | $54.6M | $49.9M | $39.5M | $45.9M |
| Total operating expenses | $59.6M | $50.1M | $54.7M | $59.4M | $62.8M | $85.4M | $59.6M | $62.8M | $66.5M | $63.3M | $50.3M | $57.3M |
| Operating income | $10.1M | $17.4M | −$10.9M | $18.5M | −$30.0M | −$57.4M | −$27.9M | $5.7M | $11.9M | −$2.3M | $10.4M | $6.3M |
| Interest income | $939,000 | — | $1.1M | $790,000 | $1.4M | — | — | — | $1.4M | $1.5M | $1.5M | — |
| Interest expense | — | — | — | — | — | — | — | — | — | — | $1.8M | — |
| Income before taxes | $11.0M | $8.2M | −$20.7M | $18.8M | −$25.9M | −$54.5M | −$30.3M | $13.2M | $10.3M | −$2.2M | $13.7M | $6.7M |
| Income taxes | $3.0M | $3.0M | −$2.3M | $9.9M | −$9.1M | −$275,000 | $3.9M | $3.2M | $3.0M | $1.1M | $6.0M | $1.9M |
| Net income | $8.1M | $5.2M | −$18.3M | $8.9M | −$16.8M | −$54.2M | −$34.2M | $10.0M | $7.4M | −$3.3M | $7.8M | $4.8M |
| EBITDA | $14.5M | $10.4M | −$18.2M | $26.4M | −$22.7M | −$32.4M | −$28.0M | $14.9M | $11.9M | −$974,000 | $15.0M | $8.1M |
| EPS (diluted) | $0.18 | $0.29 | $0.01 | $0.30 | −$0.13 | −$1.00 | −$0.69 | $0.20 | $0.39 | $0.11 | $0.16 | $0.30 |
| Gross margin | 74.5% | 72.2% | 75.7% | 82.2% | 74.0% | 65.8% | 64.7% | 77.3% | 79.2% | 78.9% | 79.6% | 79.2% |
| Operating margin | 10.8% | 18.6% | −18.9% | 19.5% | −67.6% | −134.8% | −57.0% | 6.4% | 12.0% | −2.9% | 13.6% | 7.8% |
| Net margin | 8.6% | 5.6% | −31.7% | 9.4% | −37.9% | −127.3% | −69.9% | 11.3% | 7.5% | −4.3% | 10.2% | 6.0% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in STAA's financial statements (latest annual report filed March 3, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
STAA financial results
In fiscal year 2025 (ended December 31, 2025), STAAR Surgical reported revenue of $239.4 million, down 23.7% from the year before. It had a net loss of $80.4 million, a net profit margin of −33.6%. Diluted earnings per share came to −$0.82. Over five years revenue grew at an average rate of 7.9% a year.
See the STAA stock overview for the latest quote and news, or the STAA chart for price history and technical indicators.
STAA income statement FAQ
What is STAAR Surgical's annual revenue?
STAAR Surgical reported total revenue of $239.4 million for fiscal year 2025, which ended on December 31, 2025. That was down 23.7% from $313.9 million the previous year.
Is STAAR Surgical profitable?
No. STAAR Surgical reported a net loss of $80.4 million in fiscal 2025, a net profit margin of −33.6%; its operating margin was −19.2%.
What is STAAR Surgical's gross margin?
STAAR Surgical's gross margin was 76.2% in fiscal 2025: for every $100 of revenue, STAAR Surgical kept $76 after the direct cost of its products and services.
How much does STAAR Surgical spend on research and development?
STAAR Surgical spent $40.1 million on research and development in fiscal 2025, 16.7% of revenue.
How fast is STAAR Surgical growing?
Revenue grew 7.9% a year on average over the last five fiscal years, from $163.5 million to $239.4 million.
What are STAAR Surgical's earnings per share?
STAAR Surgical earned $-0.82 per diluted share in fiscal 2025, compared with $0.01 a year earlier.
When will STAAR Surgical report its next earnings?
STAAR Surgical is expected to report results for the quarter ending September 30, 2026 on November 4, 2026.
When does STAAR Surgical's fiscal year end?
STAAR Surgical's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 3, 2026.